"Wegovy: FDA-Approved Weight-Loss Drug Reduces Heart Disease Risks"
TL;DR Summary
The FDA has approved Wegovy, a weight loss drug, to reduce the risk of heart attack and stroke, making it the first therapy in the US to help manage weight and lower heart disease risk. The drug's label has been updated to reflect this new indication, following a clinical trial that showed a 20% reduction in cardiovascular events compared to a placebo. Wegovy contains semaglutide, the same active ingredient found in the diabetes drug Ozempic, and its approval could lead to increased coverage by employers and insurers.
- FDA approves Wegovy to reduce heart attack and stroke risk NBC News
- Weight-loss drug Wegovy can be marketed for heart benefits after FDA label update CNN
- Novo Nordisk's Wegovy wins FDA approval for cutting heart disease risks, in move that could expand insurance coverage CNBC
- Anti-obesity drug Wegovy can be prescribed for heart problems, FDA says Axios
- FDA approves weight-loss drug Wegovy to reduce heart-disease risks The Washington Post
Reading Insights
Total Reads
0
Unique Readers
10
Time Saved
1 min
vs 2 min read
Condensed
68%
272 → 87 words
Want the full story? Read the original article
Read on NBC News